These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Should we use outpatient dobutamine or milrinone? Kato M; Sanada S; Kitakaze M Circ Heart Fail; 2009 Jul; 2(4):377-8. PubMed ID: 19808362 [No Abstract] [Full Text] [Related]
8. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Gorodeski EZ; Chu EC; Reese JR; Shishehbor MH; Hsich E; Starling RC Circ Heart Fail; 2009 Jul; 2(4):320-4. PubMed ID: 19808355 [TBL] [Abstract][Full Text] [Related]
9. Intravenous inotropic agents in the intensive therapy unit: do they really make a difference? Opasich C; Russo A; Mingrone R; Zambelli M; Tavazzi L Eur J Heart Fail; 2000 Mar; 2(1):7-11. PubMed ID: 10742697 [TBL] [Abstract][Full Text] [Related]
10. [Combination therapy; dobutamine and milrinone]. Kato M; Hirayama A Nihon Rinsho; 2011 Nov; 69 Suppl 9():428-33. PubMed ID: 22724242 [No Abstract] [Full Text] [Related]
11. Critical care. Inotrope therapy. Place B Nurs Times; 1996 Aug 28-Sep 3; 92(35):55-7. PubMed ID: 8868896 [No Abstract] [Full Text] [Related]
12. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study]. Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738 [TBL] [Abstract][Full Text] [Related]
13. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261 [TBL] [Abstract][Full Text] [Related]
14. [Catecholamines use in patients with heart failure]. Iino K; Ito H Nihon Rinsho; 2007 May; 65 Suppl 5():30-3. PubMed ID: 17571362 [No Abstract] [Full Text] [Related]